Vida Health

Who they are now

A clinic without a waiting room

Somewhere right now, a person with prediabetes opens an app instead of a pill bottle. A coach texts back. A dietitian reviews last night's dinner. A therapist asks about the stress that has been quietly raising the blood pressure all along. No parking lot. No clipboard. No three-week wait for a fifteen-minute visit.

That is Vida Health on an ordinary Tuesday. It is a digital health company that treats chronic conditions - obesity, diabetes, hypertension - alongside the depression and anxiety that tend to ride shotgun. It sells not to patients directly but to the employers and health plans that quietly foot the bill for chronic disease: Boeing, Cisco, Prudential, Humana, Centene. The members get an app. The buyers get a number they can defend to a CFO.

Above: the Vida "V" - one half blue, one half magenta, like a bird that couldn't decide whether to be calm or alarmed. Fitting, for a company that treats both.

The problem they saw

Chronic disease is a relationship, not a transaction

American healthcare is exceptionally good at episodes. You break, it fixes. The trouble is that obesity and diabetes do not break - they accumulate, quietly, over years, between the rare appointments where anyone is actually watching. And the conditions arrive in pairs. Diabetes brings depression. Obesity brings anxiety. The body and the mind keep the same calendar, but the healthcare system insists on booking them in different buildings.

The cost of getting this wrong is not abstract. Chronic conditions drive the majority of healthcare spending, and the bill lands on self-insured employers and health plans who would very much like it to stop growing. The old answer was a stack of disconnected point solutions - one app for weight, another for mood, a third for diabetes - none of them talking to each other. The patient, predictably, fell through the seams.

Vida's founding wager was that continuity beats episodes, and that one clinic treating the whole person beats five apps treating fractions of one.

The founders' bet

A payments executive walks into healthcare

Stephanie Tilenius founded Vida in 2014. Her resume was, on paper, an odd fit: vice president of Commerce and Payments at Google, and before that an investor at Kleiner Perkins who had backed Nextdoor and MyFitnessPal. She knew consumer software, scale, and habits - which, it turns out, is most of what chronic disease management actually requires.

The bet she made was contrarian for its moment. While much of digital health chased pure automation - chatbots, algorithms, the dream of care without clinicians - Vida insisted on keeping humans in the loop. AI would personalize and scale. Coaches, dietitians, therapists, and physicians would provide the connection that makes a person actually change a habit. The unfashionable claim was that you needed both, and that neither alone would move an A1c.

Nine years later, in November 2023, Tilenius stepped down. Joe Murad - who had led WithMe Health and, earlier, PokitDok before its acquisition by Change Healthcare - took the CEO seat and a board chair, arriving with a brief to scale the bet rather than rewrite it.

The product

One app, four kinds of help

The Vida app is deceptively plain: video sessions, messaging, digital content. What sits behind it is a virtual cardiometabolic clinic. A member can prevent, manage, or reverse a chronic condition while also working on the mental health that surrounds it - all inside one login, with one care team that shares notes.

The detail that gives the game away is the GLP-1 discipline. In an era where weight-loss drugs are prescribed almost reflexively, Vida brags about restraint: in its managed Quantum Health program, only about 14% of members start on a GLP-1, against the 40-50% typical of unmanaged care. The product begins with behavior change and reaches for the expensive drug only when it is genuinely needed. It is a rare company that markets how little it sells.

The proof

Numbers, partners, and a published A1c

Skepticism is the correct posture toward digital health, an industry that has sold a great deal of engagement and rather less outcome. Vida's answer is to point at the data it has put in peer review. Its virtual diabetes program published clinically meaningful HbA1c reductions in JMIR Diabetes. Its Spanish-language program cut A1c by an average of 1.23 points from a 9.65 baseline in four months - with bigger drops for the more engaged.

The partnerships read like a vote of confidence from people who scrutinize claims for a living. Amwell embedded Vida inside its own platform as "Cardiometabolic Care Powered by Vida." Quantum Health made Vida the exclusive GLP-1 solution across 500+ self-insured employers and more than three million members. And the client list - Boeing, Bass Pro Shops, Cisco, Prudential, alongside health plans like Humana and Centene - is the kind that does not sign without a procurement department asking hard questions.

The mission

Continuous, connected, collaborative

Vida describes its mission as using technology to deliver continuous, connected, and collaborative healthcare that drives better outcomes at lower cost. Strip the adjectives and it amounts to a single idea: care should not stop between appointments, and it should not treat a person in pieces.

That is why the company keeps widening the circle rather than narrowing it. In 2026 it added support for MASH - metabolic dysfunction-associated steatohepatitis, the fatty-liver disease hiding inside the obesity crisis and a fast-growing cost driver. The logic is consistent: cardiometabolic health is one tangled system, so a clinic that treats it ought to follow the tangle wherever it leads.

It is, admittedly, a tidy story. Healthcare rarely cooperates with tidy stories. But the through-line from 2014 to now has not wobbled - body and mind, together, measured, and answerable to the people paying the bill.

Why it matters tomorrow

The GLP-1 reckoning is coming

GLP-1 drugs work, and they are expensive enough to bankrupt a benefits budget if handed out freely. Every employer in America is now staring at the same arithmetic. The company that can deliver the outcomes while controlling who actually needs the drug is positioned for the exact moment the market is walking into. Vida built that discipline before it was fashionable.

Whether it wins is an open question - Omada, Teladoc, Hinge, Virta, and a crowded field are chasing the same buyers. But the bet is clearer than ever: AI to scale, humans to stick the landing, and one clinic for the whole person.

So back to that ordinary Tuesday. The person with prediabetes still opens the app instead of the pill bottle. But now the coach, the dietitian, and the therapist are reading from the same chart - and a year later the A1c is lower, the anxiety is quieter, and nobody had to find parking. The waiting room is gone. The waiting, mostly, is too.

Watch & explore

Go deeper